Aicuris Gmbh + Co. Kg.

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Bayer Animal Health Gmbh

Aicuris Anti-infective Cures Gmbh

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Elanco Animal Health Gmbh

Alcafleu Management Gmbh & Co. Kg.

Mathias Berwe

Oliver Kuhn

Hans-Christian Militzer

Wilfried Schwab

Christian R Thomas

Käthe Gooβen

Joachim Kruger

Peter Fey

Alexander Straub

Reinhold Gehring

Alfons Grunenberg

Herbert Diehl

Ralf Wischnat

Klaus Mohrs

Birgit Keil

Michael Lögers

Edwin Aret

Michael Limmert

Joachim Rehse

Hans-Peter Wirges

Joachim Krüger

Werner Heilmann

Kerstin Paulus

Christian Schickaneder

Jana Lenz

Juergen Stiehl

Karl-Heinz Wahl

Clemens Bothe

Markus Longerich

Mike Matthäus

Jürgen Stiehl

Dirk Grotjohann

Karl Rittner

Joerg Wirths

Kathe Goossen

Nicole Rindermann

Welljanne Martens

Dirk Jung

Antje Dietzel

Matthias Müller-Gliemann

Käthe Goossen

Welljanne MÄRTENS

Jörg Wirths

Joachim Krueger

Kaethe Goossen

Matthias Mueller-Gliemann

Mike Matthaeus

Michael Loegers

Quinolonecarboxylic esters of the general formula (II) are hydrolyzed to quinolonecarboxylic acids of the general formula (I):  The method comprises the step A): A) reacting compounds of the formula (II) with a mixture comprising acetic acid, sulfuric acid and water In step A), &#x2265;30 to &#x2264;40 mol of acetic acid, &#x2265;0.3 to &#x2264;1 mol of sulfuric acid and &#x2265;0.9 to &#x2264;2.5 mol of water are used per mole of compounds of the formula (II). The method is particularly suitable for the synthesis of the intermediate (I) in the synthesis of pradofloxacin.

Method for the hydrolysis of quinolonecarboxylic esters

The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30&#xb0; C. to 60&#xb0; C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration

The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses.

Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents

Dihydroquinazolines of the formula:  The dihydroquinalzolines are useful as antiviral agents in particular against cytomegaloviruses.

Process for the preparation of dihydroquinazolines

The present invention relates to a process for the preparation of dihydroquinazolines, for example, methyl (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoro -methyl)-phenyl]-3,4-dihydroquinazolin-4-yl}acetate (2S,3S)-2,3-bis[(4-methylbenzoyl) -oxy]succinic acid salt, which are used for the production of antiviral medicaments. 

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoro-methyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide and its tosylate salt.

Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide

The present invention relates to a process for the preparation of dihydroquinazolines, for example {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid, which are used as antiviral agents in the production of medicaments.

The present invention relates to a process for preparing 4-(4-aminophenyl)-3-morpholinone by reacting 4-(4-nitrophenyl)-3-morpholinone with hydrogen in the presence of a hydrogenation catalyst, characterized in that the reaction is effected in an aliphatic alcohol.

Method for the production of 4-(4-aminophenyl)-3-morpholinone

The present invention relates to a process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide starting from 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione, 4-(4-aminophenyl)-3-morpholinone and 5-chlorothiophene-2-carbonyl chloride.

Preparation process

The invention relates to a process for the preparation of nifedipine by the reaction of methyl 2-(2-nitrobenzylidene)acetoacetate and methyl 3-aminocrotonate and the use of the nifedipine thus prepared for the production of a medicament.

Process for preparing nifedipine

Growing community of inventors

Sprockhövel, Germany

Mathias Berwe